| Literature DB >> 35658582 |
Eman Husssein Alshdaifat1, Sami Saif El-Deen Al-Horani2, Majd Mahmoud Al-Sous2, Sharaf Al-Horani3, Fernas Emile Sahawneh1, Amer Mahmoud Sindiani3.
Abstract
BACKGROUND: Abnormal uterine bleeding (AUB) is a symptom that deviates from the normal menstrual cycle. AUB is characterized by changes in the frequency, volume, and duration of the menstrual flow. The etiology of AUB, which varies with age, may be attributed to both structural and non-structural causes.Entities:
Mesh:
Year: 2022 PMID: 35658582 PMCID: PMC9167457 DOI: 10.5144/0256-4947.2022.204
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.707
Demographic and clinical characteristics by age group (n=3233).
| 18–39 (n=1412) | 40–49 (n=1125) | ≥50 (n=696) | ||
|---|---|---|---|---|
| Age (years) | 41 (16) | 33 (7) | 45 (7) | 53 (7) |
| Functional endometrium | 1867 | 810 | 740 | 317 |
| Proliferative phase | 1066 (57.1) | 422 (52.1) | 422 (57.0) | 222 (70.0) |
| Secretory phase | 801 (42.9) | 388 (47.9) | 318 (43.0) | 95 (30.0) |
| Inflammatory endometrium | 48 | 17 | 24 | 7 |
| Acute endometritis | 5 (10.4) | 2 (11.8) | 2 (8.3) | 1 (14.3) |
| Chronic endometritis | 42 (87.5) | 15 (88.2) | 21 (87.5) | 6 (85.7) |
| Endometrial tuberculosis | 1 (2.1) | 0 (0.0) | 1 (4.2) | 0 (0.0) |
| Endometrial atrophy | 19 | 0 | 2 | 17 |
| Atrophic endometrium | 19 (100) | 0 (0.0) | 2 (100) | 17 (0.0) |
| Endometrial hyperplasia | 27 | 6 | 4 | 17 |
| Simple hyperplasia without atypia | 9 (33.3) | 2 (33.3) | 1 (25.0) | 6 (35.3) |
| Simple hyperplasia with atypia | 4 (14.8) | 1 (16.7) | 0 (0.0) | 3 (17.6) |
| Complex hyperplasia without atypia | 4 (14.8) | 0 (0.0) | 2 (50.0) | 2 (11.8) |
| Complex hyperplasia with atypia | 10 (37) | 3 (33.3) | 1 (25.0) | 6 (35.3) |
| Benign lesions | 456 | 111 | 161 | 184 |
| Benign endometrial polyp | 453 (99.3) | 111 (100) | 160 (99.4) | 182 (98.9) |
| Leiomyoma | 3 (0.7) | 0 (0.0) | 1 (0.6) | 2 (1.1) |
| Malignant lesions | 55 | 2 | 5 | 48 |
| Endometrioid adenocarcinoma | 42 (76.4) | 2 (100) | 4 (80.0) | 36 (75.0) |
| Serous carcinoma | 7 (12.7) | 0 (0.0) | 1 (20.0) | 6 (12.5) |
| Mixed mullerian tumor | 5 (9.1) | 0 (0.0) | 0 (0.0) | 5 (10.4) |
| Endometrial stromal neoplasm | 1 (1.8) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Pregnancy related | 566 | 441 | 123 | 2 |
| Products of conception (Normal pregnancy) | 560 (98.9) | 437 (99.1) | 121 (98.4) | 2 (100) |
| Partial molar pregnancy | 3 (0.5) | 2 (0.5) | 1 (0.8) | 0 (0.0) |
| Complete molar pregnancy | 2 (0.4) | 2 (0.5) | 0 (0.0) | 0 (0.0) |
| Arias-Stella reaction | 1 (0.2) | 0 (0.0) | 1 (0.8) | 0 (0.0) |
| Miscellaneous | 195 | 25 | 66 | 104 |
| Inactive endometrium | 60 (30.8) | 4 (16.0) | 23 (34.8) | 33 (31.7) |
| Hormonal effect | 33 (16.9) | 6 (24.) | 14 (21.2) | 13 (12.5) |
| Autolyzed endometrium | 1 (0.5) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
| Unidentified/Inadequate | 101 (51.8) | 15 (60.0) | 29 (43.9) | 57 (54.8) |
Data are n (%) except for age (median and interquartile range)
Demographic and clinical characteristics by parity (n=3233).
| Nulliparous (n=536) | Multiparous (n=2696) | ||
|---|---|---|---|
| Age (years) | 41 (16), 19–86 | 33 (13), 19–82 | 43 (13), 19–86 |
| Functional endometrium | 1867 | 361 | 1506 |
| Proliferative phase | 1066 (57.1) | 201 (55.1) | 865 (57.4) |
| Secretory phase | 801 (42.9) | 160 (44.3) | 641 (42.6) |
| Inflammatory endometrium | 48 | 4 | 44 |
| Acute endometritis | 5 (10.4) | 0 (0.0) | 5 (11.4) |
| Chronic endometritis | 42 (87.5) | 4 (100.0) | 38 (86.4) |
| Endometrial tuberculosis | 1 (2.1) | 0 (0.0) | 1 (2.3) |
| Endometrial atrophy | 19 | 3 | 16 |
| Atrophic endometrium | 19 (100) | 3 (100.0) | 16 (100.0) |
| Endometrial hyperplasia | 27 | 8 | 19 |
| Simple hyperplasia without atypia | 9 (33.3) | 3 (37.5) | 6 (31.6) |
| Simple hyperplasia with atypia | 4 (14.8) | 1 (12.5) | 3 (15.8) |
| Complex hyperplasia without atypia | 4 (14.8) | 1 (12.5) | 3 (15.8) |
| Complex hyperplasia with atypia | 10 (37) | 3 (37.5) | 7 (36.8) |
| Benign lesions | 456 | 67 | 389 |
| Benign endometrial polyp | 453 (99.3) | 67 (100.0) | 386 (99.2) |
| Leiomyoma | 3 (0.7) | 0 (0.0) | 3 (0.8) |
| Malignant lesions | 55 | 12 | 43 |
| Endometrioid adenocarcinoma | 42 (76.4) | 10 (83.3) | 32 (74.4) |
| Serous carcinoma | 7 (12.7) | 1 (8.3) | 6 (14.0) |
| Mixed mullerian tumor | 5 (9.1) | 1 (8.3) | 4 (9.3) |
| Endometrial stromal neoplasm | 1 (1.8) | 0 (0.0) | 1 (2.3) |
| Pregnancy related | 566 | 70 | 496 |
| Products of conception (Normal pregnancy) | 560 (98.9) | 70 (100.0) | 490 (98.8) |
| Partial molar pregnancy | 3 (0.5) | 0 (0.0) | 3 (0.6) |
| Complete molar pregnancy | 2 (0.4) | 0 (0.0) | 2 (0.4) |
| Arias-Stella reaction | 1 (0.2) | 0 (0.0) | 1 (0.2) |
| Miscellaneous | 195 | 11 | 183 |
| Inactive endometrium | 60 (30.8) | 4 (36.4) | 55 (30.1) |
| Hormonal effect | 33 (16.9) | 2 (18.2) | 31 (16.9) |
| Autolyzed endometrium | 1 (0.5) | 0 (0.0) | 1 (0.5) |
| Unidentified/Inadequate | 101 (51.8) | 5 (45.5) | 96 (52.5) |
Data are n (%) except for age (median interquartile range and minimum-maximum)
Diagnostic accuracy of D&C versus histopathological findings after hysterectomy (n=277).
| Sensitivity | Specificity | Positive predictive value | Negative predictive value | Accuracy | |
|---|---|---|---|---|---|
| Normal vs pathologic | 72.9 | 77.9 | 73.86 | 77.05 | 75.60 |
| Premalignant (endometrial hyperplasia) | 81.82 | 97.92 | 75.00 | 98.60 | 96.77 |
| Malignant) | 100 | 99.3 | 97.56 | 100 | 99.45 |
| Premalignant and malignant | 96.15 | 97.24 | 92.59 | 98.6 | 96.95 |
Values are percent.
Comparison between D&C and hysterectomy endometrioid adenocarcinoma grading.
| Grade (G) | D&C | Hysterectomy | Upgraded | Downgraded |
|---|---|---|---|---|
| G1 | 17 | 14 | 4 (23.5%) to Grade 2 | - |
| G2 | 9 | 12 | 1 (11.1%) to Grade 3 | 1 (11.1%) to Grade 1 |
| G3 | 4 | 4 | - | 1 (25.0%) to Grade 2 |
| Total | 30 | 30 | 5 (16.67%) | 2 (6.67%) |
Grade 1: 5% or less of tumor tissue is solid tumor growth. The cancer cells are well-differentiated.
Grade 2: 6%–50% of tissue is solid tumor growth. The cancer cells are moderately differentiated.
Grade 3: More than 50% of tissue is solid tumor growth. The cancer cells are poorly differentiated.